FUNDING THE BEST BRAINS TO BEAT BRAIN CANCER
Dr Charlie Teo AM, Professor of Neurosurgery
Director and Founder, Charlie Teo Foundation
FUNDER PROFILE
Filmed in Sydney, Australia | December 2024
The Charlie Teo Foundation is dedicated to funding and advancing research into brain cancer, with a particular focus on developing more effective treatments and finding a cure for this devastating disease. The foundation’s mission includes:
- Supporting cutting-edge research: The foundation funds innovative research into brain cancer, aiming to discover new therapies, improve outcomes, and ultimately find a cure.
- Raising awareness: The foundation works to increase public awareness about brain cancer, its impact on patients and families, and the need for more research and funding in this field.
- Helping patients: In addition to supporting research, the foundation assists individuals and families affected by brain cancer by providing information, resources, and support.
- Advocating for change: It strives to drive systemic change in how brain cancer is researched and treated, challenging the status quo and encouraging collaboration and innovation within the medical community.
Dr. Charlie Teo AM as the Founder and Director of the Charlie Teo Foundation, has for over 30 years been instrumental in the development, dissemination and acceptance of the concept of keyhole minimally invasive techniques in neurosurgery. Dr Teo ran a fellowship program that attracts over 600 applicants yearly and has trained many of the world’s leading figures in neurosurgery. He has trained at distinguished centres such as the Barrow Neurological Institute, Johns Hopkins University, Duke University, Stanford University, Vanderbilt University and Harvard University.
Initially focused on Australia, Dr Teo recognised a pressing need to raise funds for brain cancer research from a young age. To address this, he founded the Charlie Teo Foundation in 2017, which aims to increase awareness and funding for brain cancer research.
Brain cancer significantly impacts society, being the leading cause of years of life lost. Despite its high incidence, particularly among young adults and children, it remains one of the least funded cancers. The foundation operates with low overhead costs and focuses on supporting disruptive researchers who think outside the box.
Since its inception, the foundation has committed nearly $15 million to brain cancer research, funding notable projects in Australia and the United States. These projects explore innovative approaches to understand and treat brain cancer more effectively, with a focus on translating findings from animal studies to human applications. Charlie’s dedication to finding solutions for this devastating disease remains unwavering as he travels frequently to collaborate with global researchers.
You Might also like
-
DNA repair on the Fanconi anaemia pathway
Associate Professor Wayne Crismani is an internationally recognised expert in DNA repair, with a particular focus on Fanconi anaemia (FA)—a cancer-predisposition and bone marrow failure syndrome marked by extreme sensitivity to DNA damage. Based at St Vincent’s Institute in Melbourne, he leads a research program dedicated to understanding the genetic, cellular, and reproductive consequences of FA. He is currently supported by a Victorian Cancer Agency Mid-Career Fellowship and funding from the National Health and Medical Research Council.
-
Better biomarkers for predicting the incidence of having atherosclerosis and heart attack
Assoc Prof Bursill is a vascular biologist with interests and expertise in vascular inflammation, atherosclerosis and angiogenesis. She completed her PhD at The University of Adelaide in lipid metabolism then headed to Oxford University for five years to undergo a postdoctoral post in the Departments of Cardiovascular Medicine and Pathology. Her postdoctoral time triggered her interest in the mechanisms that cause atherosclerosis and in particular the role of small inflammatory proteins called chemokines.
-
Professor Christoph Hagemeyer
RESEARCH IN NANOBIOTECHNOLOGY
@ MONASH UNIVERSITY
VICTORIA, AUSTRALIA